Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy

European Journal of Neurology

Volumn 14, Issue 4, 2007, Pages 391-398

  Lebrun, C ^a   Fontaine, D ^a   Bourg, V ^a   Ramaioli, A ^a   Chanalet, S ^a   Vandenbos, F ^a   Lonjon, M ^a   Fauchon, F ^a   Paquis, P ^a   Frenay, M ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Brain tumor; Chemotherapy; Glioma; Oligodendroglioma; PCV; Prognosis

Indexed keywords

CISPLATIN; ETOPOSIDE; FOTEMUSTINE; GADOLINIUM; LOMUSTINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG METABOLISM; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; WORLD HEALTH ORGANIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOMUSTINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 33947604513     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01675.x     Document Type: Article

References (43)

1. Van den Bent M, Chinot OL, Cairncross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology 2003; 5: 128-138.
2. CBTRUS. Primary Brain Tumors in the United States. Statistical Report 1997-2001. Hinsdale: CBTRUS, 2004.
3. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Journal of Neurosurgery 1994; 35: 1018-1035.
4. Olson JD, Riedel E, De Angelis L. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000; 54: 1442-1448.
5. Lebrun C, Fontaine D, Ramaioli A, et al. Long-term outcome of oligodendrogliomas. Neurology 2004; 62: 1783-1787.
6. Cairncross JG, Mac Donald DR. Successful chemotherapy for recurrent malignant oligodendrogliomas. Annals of Neurology 1998; 23: 360-364.
7. Sanson M, Leuraud P, Marie Y, Delattre JY, Hoang-Xuan K. Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas. Annals of Neurology 2002; 52: 105-107.
8. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patients management at diagnosis. Clinical Cancer Research 2001; 7: 839-845.
9. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlations with chromosome 1p deletions. Journal of Clinical Oncology 2004; 22: 3133-3138.
10. Buckner JC, Gesme D, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. Journal of Clinical Oncology 2003; 21: 251-255.
11. Pignatti F, Van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral lowgrade glioma. Journal of Clinical Oncology 2002; 20: 2076-2084.
12. Wallner KR, Gonzales M, Sheline GE. Treatment of oligodendrogliomas with or without postoperative irradiation. Journal of Neurosurgery 1988; 68: 684-688.
13. Yeh SA, Lee TC, Chen HJ, et al. Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendrogliomas. International Journal of Radiation Biology and Physics 2002; 54: 1405-1409.
14. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomized trial. Lancet 2005; 366: 985-990.
15. Karim ABMF, Afra D, Cornu PH, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council Study BR04: An interim analysis. International Journal of Radiation Oncology, Biology, Physics 2002; 52: 316-324.
16. Higuchi Y, Iwadate Y, Yamaura A. Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 2004; 63: 2384-2386.
17. Biemond-ter Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine and vincristine. Cancer 2005; 103: 802-809.
18. World Health Organization. Tumors of the Nervous System, Pathology and Genetic Classification of Tumors. Kleihues P, Cavenee WK, eds. Lyon: IARC Press, 2000.
19. Frénay M, Lebrun C, Lonjon M, et al. Up-front chemotherapy with fotemustine (F)/cisplatine (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. European Journal of Cancer 2000; 36: 1026-1031.
20. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of Clinical Oncology 2001; 19: 2449-2455.
21. MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology 1990; 8: 1277-1280.
22. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of Neurology 1992; 31: 431-436.
23. Van Veelen MLC, Avezaat CJJ, Kros JM, Van Putten W, Vecht C. Supra-tentorial low grade astrocytoma: prognostic factors, dedifferentiation and the issue of early versus late surgery. Journal of Neurology, Neurosurgery and Psychiatry 1998; 64: 581-587.
24. Duffau H, Lopes M, Arthuis F, et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series and with (1996-2003) functional mapping in the same institution. Journal of Neurology, Neurosurgery and Psychiatry (1985-1996) 2005; 845-851.
25. Shaw EG, Arusell R, Scheithauer B, et al. A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a NCCTG-RTOG-ECOG study. Journal of Clinical Oncology 2002; 20: 2267-2276.
26. Taphoorn MJ, Schiphorst AR, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Annals of Neurology 1994; 36: 48-54.
27. Brown PD, Buckner JC, Uhm JH, Shaw EG. The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-oncology 2003; 5: 161-167.
28. Surma-aho O, Niemella M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001; 56: 1285-1290.
29. Cairncross G, Seiferheld W, Shaw R, et al. An intergroup randomized controlled clinical trial of chemotherapy plus radiation versus radiation alone for pure and mixed anaplstic oligodendrogliomas: initial report of RTOG94-02. American Journal of Clinical Oncology; ASCO Proceedings 2005; 1500.
30. van den Bent MJ, Delattre JY, Brandes AA, et al. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Americal Journal of Clinical Oncology; ASCO Proceedings 2005; 1503.
31. Mason WP, Krol GS, De Angelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203-207.
32. Frénay MP, Fontaine D, Vandenbos F, Lebrun C. First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. European Journal of Neurology 2005; 12: 685-690.
33. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II patients. Annals of Oncology 2003; 14: 1715-1721.
34. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade gliomas. Journal of Clinical Oncology 2003; 21: 646-651.
35. Pace A, Vidiri A, Galie E, Carasi M, Telera S, Cianciulli AM, Canalini P et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Annals of Oncology 2003; 14: 1722-1726.
36. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European organization for research and treatment of cancer brain tumor group study 26971. Journal of Clinical Oncology 2003; 21: 2525-2528.
37. Streffer J, Schabet M, Bamberg M, et al. A role for pre irradiation PCV chemotherapy for oligodendroglial brain tumors. Journal of Neurology 2000; 247: 297-302.
38. Triebels V, Taphoorn MJ, Brandes A, et al. Salvage PCV chemotherapy for temozolomide resistant oligodendrogliomas. Neurology 2004; 63: 904-906.
39. Soffietti R, Ruda R, Bradac GB, Boldorini R. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43: 1066-1073.
40. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Annals of Neurology 2003; 53: 524-528.
41. Van den Bent MJ, Chinot O, Boogert W, et al. A second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV chemotherapy: EORTC brain tumor group phase II study 26972. Annals of Oncology 2003; 14: 599-602.
42. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006; 66: 1661-1667.
43. Soffietti R, Nobile M, Ruda R, et al. Second-line treatment with carboplatine for recurrent or progressive oligodendroglial tumors after PCV chemotherapy: a phase II study. Cancer 2004; 100: 807-813.